Anti-Mullerian hormone and puberty development in girls and adolescents who underwent cancer treatment

Ayuandari, Sarrah; Dewanto, Agung; Oktasari, Rizki; Rahmawati, Naafi Rizqi; Alma, Nurulita Ainun; Hamurajib, Kuky Cahya; Mulatsih, Sri

doi:10.1007/s00404-021-06364-5

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most chemotherapy drugs cause reproductive toxicity in women, disrupting physiological homeostasis and adversely affecting many organs, especially in younger pa-tients [21]. Despite the fact that chemotherapeutics can be used to treat numerous types of cancer, ovarian toxicity in young female cancer patients must never be overlooked.…”

Section: Discussionmentioning

confidence: 99%

Protective Effect and Mechanism of Melatonin on Cisplatin-Induced Ovarian Damage in Mice

Xing

Wang

Ding

et al. 2022

JCM

View full text Add to dashboard Cite

Chemotherapeutics’ development has enhanced the survival rate of cancer patients; however, adverse effects of chemotherapeutics on ovarian functions cause fertility loss in female cancer patients. Cisplatin (CP), an important chemotherapeutic drug for treating solid tumors, has adversely affected ovarian function. Melatonin (MT) has been shown to have beneficial effects on ovarian function owing to its antioxidative function. In this research, an animal model was established to explore the effect of MT on CP-induced ovarian damage. Immunohistochemical analysis and Western blot were also used to explore its mechanism. This study reported that MT protects mouse ovaries from CP-induced damage. Specifically, MT significantly prevented CP-induced ovarian reserve decline by maintaining AMH and BMP15 levels. We also found that MT ameliorated CP-induced cell cycle disorders by up-regulating CDC2 expression, and inhibited CP-induced ovarian inflammation by decreasing IL-1β and IL-18 levels. Moreover, MT protected the ovary from CP-induced mitochondrial damage, as reflected by restoring mitochondria-related protein expression. Furthermore, CP caused ovarian apoptosis, as indicated by up-regulated BAX expression. MT was also shown to activate the MAPK pathway. Our results showed that MT could ameliorate ovarian damage induced by CP, implying that MT may be a viable alternative to preserve female fertility during CP chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Protective Effect and Mechanism of Melatonin on Cisplatin-Induced Ovarian Damage in Mice

Xing

Wang

Ding

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…The rats (n = 48) were randomly divided into four experimental groups (12 animals per group): 1 control group, 2 POF group, 3 10 mg/kg melatonin (MT10), and 4 20 mg/kg melatonin (MT20). The CTX-induced POF rats model was established according to the previous studies.…”

Section: Methodsmentioning

confidence: 99%

“…1 About 60-80% of chemotherapy patients may experience POF. 2 CTX, as an alkylating agent commonly used in chemotherapy, induces severe ovarian damage and is a recognized risk of POF. 3,4 Studies have shown that CTX causes ovarian follicle failure by activating primal follicles and making them lose a lot.…”

Section: Introductionmentioning

confidence: 99%

Melatonin Protects Against Cyclophosphamide-induced Premature Ovarian Failure in Rats

Bao

Kong

et al. 2022

Hum Exp Toxicol

View full text Add to dashboard Cite

This study was designed to understand the efficacy and molecular cues of melatonin in cyclophosphamide(CTX)-induced premature ovarian failure (POF) in rats. Female SD rats were used to evaluate the potential effects of melatonin on the ovarian hormonal status, follicular development, and granulosa cells in CTX-treated rats. Here, we found that pretreatment with melatonin before CTX administration preserved the normal sex hormone levels, improved follicular morphology, and granulosa cell proliferation, and reduced apoptosis, as compared to the CTX treatment alone. Additionally, melatonin also up-regulated CYR6 and CTGF at the mRNA and protein levels. A potential mechanism is that melatonin inhibits LATS1, Mps1-One binder (MOB1), and YAP phosphorylation, thereby activating the Hippo signal pathway to promote its downstream targets, CYR61 and CTGF. In conclusion, pretreatment with melatonin effectively protected the ovaries against CTX-induced damage by activating the Hippo pathway. This study lay the foundation for the clinical application of melatonin for cancer patients with CTX treatment.

show abstract

“…6,7 Our previous study showed that, overall, chemotherapy can affect the ovarian reserve with regards to AMH level, altered menstrual regularity, as well as delayed pubertal development. 8 However, the correlation between cumulative dose of high-risk gonadotoxic agents such as cyclophosphamide and AMH levels has not been studied.…”

mentioning

confidence: 99%

Cumulative cyclophosphamide dose and serum anti-Mullerian hormone levels in adolescent cancer survivors in Indonesia

Mulatsih,

Ayuandari,

Rahmawati

et al. 2023

View full text Add to dashboard Cite

Background As both the prevalence and survival rates of cancer in children and adolescents has risen, longer-term effects of cancer treatment must be investigated. High-risk gonadotoxic chemotherapeutic agents such as cyclophosphamide may affect the ovarian reserve and impact female adolescent fertility. Anti-Mullerian hormone is a reliable marker to assess ovarian reserve. Objective To assess for a possible correlation between the cumulative dose of cyclophosphamide and serum anti-Mullerian hormone (AMH) levels among adolescent cancer patients. Methods This cross-sectional study included 12-18-year-old adolescent female cancer patients who had experienced menarche and received cyclophosphamide therapy. We recorded the patients’ full history, including menstrual history, computed the cumulative dose of cyclophosphamide received, and measured serum AMH levels. The correlation test was performed to evaluate for a possible correlation between the cumulative dose of cyclophosphamide and ovarian reserve as represented by AMH levels. Results Out of 12 female adolescent cancer patients, three complained of disturbances in their menstrual cycles. Low levels of AMH (<1.5 ng/mL) were noted in five patients. Median cumulative cyclophosphamide dose was 1,000 mg/m2 (range 1,000 to 5,250 mg/m2). Cumulative cyclophosphamide dose was negatively correlated with serum AMH levels, but this correlation was not statistically significant (r=-0.316, P=0.318). Conclusion This study has not been able to show a correlation between cumulative cyclophosphamide dose and serum AMH level. Regular evaluation of fertility and involvement of fertility team is recommended in adolescents receiving high-risk gonadotoxic chemotherapeutic agents.

show abstract

Anti-Mullerian hormone and puberty development in girls and adolescents who underwent cancer treatment

Cited by 4 publications

References 24 publications

Protective Effect and Mechanism of Melatonin on Cisplatin-Induced Ovarian Damage in Mice

Protective Effect and Mechanism of Melatonin on Cisplatin-Induced Ovarian Damage in Mice

Melatonin Protects Against Cyclophosphamide-induced Premature Ovarian Failure in Rats

Cumulative cyclophosphamide dose and serum anti-Mullerian hormone levels in adolescent cancer survivors in Indonesia

Contact Info

Product

Resources

About